|
Desferrioxamine(4141. Cappellini MD, Cohen A, Eleftheriou A, Piga A, Porter J, Taher A,
editors. Guidelines for the Clinical Management of Thalassaemia [Internet]. 2nd rev
ed. Cyprus: Thalassaemia International Federation; 2008. [cited 2011 Sep 21].
Available
from:http://www.thalassaemia.org.cy/wordpress/wp-content/uploads/2012/12/Guidelines-2nd-edition-revised-ENGLISH-lo.pdf http://www.thalassaemia.org.cy/wordpress...
)
|
Deferiprone(99. Hoffbrand AV, Cohen A, Hershko C. Role of deferiprone in chelation
therapy for transfusional iron overload . Blood. 2003;102(1):17-24.,1010. Victor Hoffbrand A. Deferiprone therapy for transfusional iron
overload. Best Pract Res Clin Haematol. 2005;18(2):299-317.,1212. Mourad FH, Hoffbrand AV, Sheikh-Taha M, Koussa S, Khoriaty AI, Taher
A. Comparison between desferrioxamine and combined therapy with desferrioxamine and
deferiprone in iron overloaded thalassaemia patients. Br J Haematol.
2003;121(1):187-9.,1616. Origa R, Bina P, Agus A, Crobu G, Defraia E, Dessi C, et al.
Combined therapy with deferiprone and desferrioxamine in thalassemia major.
Haematologica. 2005;90(10):1309-14. Comment in: Haematologica.
2005;90(10):1297A.,1717. Daar S, Pathare AV. Combined therapy with desferrioxamine and
deferiprone in beta thalassemia major patients with transfusional iron overload. Ann
Hematol. 2006;85(5):315-9.,4949. Cohen AR, Galanello R, Piga A, De Sanctis V, Tricta F. Safety and
effectiveness of long-term therapy with the oral iron chelator deferiprone. Blood.
2003;102(5):1583-7.,5050. al-Refaie FN, Wonke B, Hoffbrand AV. Deferiprone-associated
myelotoxicity. Eur J Haematol. 1994;53(5):298-301.)
|
Deferasirox(2626. Cappellini MD, Cohen A, Piga A, Bejaoui M, Perrotta S, Agaoglu L, et
al. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in
patients with beta-thalassemia. Blood. 2006;107(9):3455-62. Comment in: Blood.
2006;108(5):1775-6; Blood. 2006;108(2):774-5; Blood.
2006;108(2):778.,2828. Cappellini MD, Bejaoui M, Agaoglu L, Canatan D, Capra M, Cohen A, et
al. Iron chelation with deferasirox in adult and pediatric patients with thalassemia
major: efficacy and safety during 5 years' follow-up.
Blood.2011;118(4):884-93.,3131. Pennell DJ, Porter JB, Cappellini MD, Chan LL, El-Beshlawy A,
Aydinok Y, et al. Continued improvement in myocardial T2* over two years of
deferasirox therapy in °-thalassemia major patients with cardiac iron overload.
Haematologica 2011;96(1):48-54. Comment in: Haematologica.
2011;96(1):5-8.,3232. Pennell DJ, Porter JB, Cappellini MD, Chan LL, El-Beshlawy A,
Aydinok Y, et al. Deferasirox for up to 3 years leads to continued improvement of
myocardial T2* in patients with °-thalassemia major. Haematologica.
2012;97(6):842-8.)
|